 Dear Reader, Dr. Mark Skousen here. Elon Musk already made me about $800,000 richer. Years ago, I got into a Tesla-heavy fund before anyone believed in him. Back when the "smart money" said electric cars were a joke. When the media was writing his obituary every other week. I ignored them all. I trusted my research. I bet big. That single bet turned into a near seven-figure position in under a decade. Now I'm betting on Elon again — with SpaceX. Bloomberg is calling the upcoming IPO "the biggest listing of ALL TIME." A $1.5 TRILLION valuation. And after meeting Elon face-to-face at a private gathering of Wall Street elites, and throwing myself into my research, I'm convinced the announcement is coming soon. March 26, 2026. That's my prediction. I have an "access code" that lets you grab a pre-IPO stake before it happens. I’d like to share it with you… Elon already helped me make a small fortune. I believe he's about to do it again — for anyone smart enough to get in early. Click here to see how to get your pre-IPO “access code”. Yours for peace, prosperity, and liberty, AEIOU, Dr. Mark Skousen
Macroeconomic Strategist, The Oxford Club P.S. I've bet on Elon before and won. Now I'm doubling down. Just click on this link to see how to join me.
Just For You CRISPR Therapeutics Gains After Earnings as Pipeline Hope GrowsBy Chris Markoch. Published: 2/19/2026. 
Key Points- CRISPR Therapeutics’ Q4 reaction reflects longer-term optimism despite weak reported revenue tied to launch economics.
- CASGEVY adoption is a key narrative driver, but profitability hinges on timing, revenue-sharing mechanics, and pipeline progress.
- With substantial cash on hand, the near-term question is technical/entry risk, while the long-term question is execution.
- Special Report: This makes me furious (From The Oxford Club)
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene-editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem surprising. The company posted a larger net loss than forecast, and revenue came in at a fraction of expectations. CRISPR is a long-term story still in the early innings. The company has moved past proof-of-concept, but investors will need patience — the payoff as it moves into a mature growth phase may be a year or two away. Putting the Earnings Report Into ContextIn December 2023, CRISPR received U.S. Food & Drug Administration (FDA) approval for CASGEVY, the company's flagship gene therapy for sickle cell disease and beta thalassemia. It was the first CRISPR/Cas9 gene-editing therapy to receive FDA approval. CRSP stock, however, is down roughly 19% since that announcement. Some of that reflects growth expectations already baked into the price; another factor is the structure of CRISPR's partnership with Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). The partnership was critical to getting CASGEVY approved, but it also includes a revenue-split arrangement that limits when CRISPR recognizes sales. Under that deal, CRISPR recognizes revenue only after Vertex has recouped a share of launch and manufacturing costs. So while CASGEVY generated $54 million in the most recent quarter, CRISPR reported quarterly revenue of just $0.86 million. That dynamic helps frame the investment thesis for CRSP stock. On one hand, more patients are receiving CASGEVY; on the other, the company is posting larger operating losses as it advances additional pipeline candidates. The key number to watch is CRISPR's cash and investments — roughly $1.9 billion — which should provide a runway of about three to four years. The Pipeline Holds the KeyEven if CASGEVY adoption accelerates, the one-time, high-cost nature of the treatment creates structural revenue-recognition challenges. These therapies often require payment arrangements that stretch out recognized revenue. That's why CRISPR's broader pipeline matters. One promising candidate is CTX611, which is being developed to reduce blood clots related to strokes and deep vein thrombosis by targeting the Factor XI protein involved in pathological clot formation while preserving normal clotting for everyday cuts and scrapes. CRISPR is testing CTX611 (SRSD107) in a Phase 2 trial for total knee arthroplasty (TKA), where post-operative blood clots are a common complication. Early human data show CTX611 has been well tolerated and produced strong, durable effects, with potential dosing as infrequently as every six weeks using the company's siRNA platform, which also enables designed reversibility. If larger trials confirm lower bleeding risk plus convenient, infrequent dosing, CTX611 could address a roughly $20 billion global anticoagulation market and become a meaningful growth driver for the company. One Thing to Check Before Getting Involved With CRSP StockAnalyst sentiment supports a "wait-and-see" stance on CRISPR Therapeutics. The consensus rating is Hold, with two Sell ratings in the mix. That includes Morgan Stanley's recent Underweight rating; the firm set a $33 price target, which would put it within approximately 10% of the stock's 52-week low. While the chart doesn't clearly support a drop that large (a fall of about 37%), CRSP was trading near its 200-day moving average as of this writing. That level has acted as support since November, and a confirmed break below it could invite more selling. 
CRSP Stock Is One to Own, Not TradeIt's been a wild ride for long-term CRSP shareholders, but the stock has delivered strong cumulative returns. Since the company's initial public offering in 2016, investors have received a total return of over 277%. Part of that performance was driven by the 2020–2021 speculative rally, which likely prompted some profit-taking. The larger point is that CRISPR Therapeutics is making progress on its pipeline, even if results are not arriving as quickly as some investors would like. CRSP may not suit short-term traders seeking sharp, immediate price moves, but it could be a good fit for investors who can tolerate volatility and have a multi-year horizon for potential gains by the end of the decade.
This ad is sent on behalf of The Oxford Club. 105 W Monument St, Baltimore, Maryland 21201. If you would like to optout from receiving offers from The Oxford Club please click here | 
No comments:
Post a Comment